Table 1.
Characteristics of GWAS.
| GWAS ID | Year | Trait | Ethnicity | Sample size | Num of SNPs |
|---|---|---|---|---|---|
| ebi-a-GCST011073 | 2020 | COVID-19 | European | 1,683,768 | 8,660,177 |
| ebi-a-GCST011081 | 2020 | COVID-19 hospitalized | European | 1,887,658 | 8,107,040 |
| ebi-a-GCST011075 | 2020 | COVID-19 severe | European | 1,388,342 | 9,739,225 |
| finn-b-E4_HYPERLIPNAS | 2021 | Hyperlipidaemi | European | 201,794 | 16,380,389 |
| ieu-b-5089 | 2022 | LDL cholesterol | European | 201,678 | 12,321,875 |
| met-d-VLDL_C | 2020 | VLDL cholesterol | European | 115,078 | 12,321,875 |
| ieu-b-109 | 2020 | HDL cholesterol | European | 403,943 | 12,321,875 |
| met-d-Total_C | 2020 | Total cholesterol | European | 115,078 | 12,321,875 |
| ieu-b-111 | 2020 | triglycerides | European | 441,016 | 12,321,875 |
| ieu-b-107 | 2020 | apolipoprotein A-I | European | 393,193 | 12,321,875 |
| met-d-ApoB_by_ApoA1 | 2020 | Ratio of apolipoprotein B to apolipoprotein A1 | European | 115,078 | 12,321,875 |
| ieu-b-108 | 2020 | apolipoprotein B | European | 439,214 | 12,321,875 |
| ukb-d-30790 raw | 2018 | Lipoprotein A | European | 377,572 | 13,583,854 |